HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tabuchi, N. Articles by Wildevuur, C. R. Search for Related Content PubMed PubMed Citation Articles by Tabuchi, N. Articles by Wildevuur, C. R.

The Annals of Thoracic Surgery, Vol 58, 1036-1039, Copyright © 1994 by The Society of Thoracic Surgeons

ARTICLES

Aprotinin preserves hemostasis in aspirin-treated patients undergoing cardiopulmonary bypass

N Tabuchi, RC Huet, A Sturk, L Eijsman and CR Wildevuur
Thorax Center, University Hospital Groningen, The Netherlands.

Various clinical trials have shown that hemostasis is improved by the administration of aprotinin during cardiopulmonary bypass. However, this effect has not been proved for those patients treated preoperatively with aspirin. Therefore, a double-blind, placebo- controlled study was conducted to test the efficacy of low-dose aprotinin (2 x 10(6) KIU in the pump prime solution) in preserving hemostasis in 40 aspirin-treated (325 mg) patients undergoing coronary artery bypass grafting. Aprotinin brought about a decrease in the postoperative blood loss (p < 0.05). The in vitro bleeding test (Thrombostat) demonstrated that aprotinin preserved the platelet hemostatic function in aspirin-treated patients during cardiopulmonary bypass (p < 0.05). The inhibitory effects of aspirin on collagen- induced platelet aggregation and thromboxane production were not influenced by aprotinin treatment. The findings from the present study indicate that aprotinin preserves hemostasis in aspirin-treated patients during cardiopulmonary bypass, but aspirin's effect on platelets is maintained. Therefore, aprotinin seems to be a useful adjunct treatment in aspirin-treated patients undergoing coronary artery bypass grafting.

This article has been cited by other articles:

				D. Fergusson, K. C. Glass, B. Hutton, and S. Shapiro Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clinical Trials, June 1, 2005; 2(3): 218 - 232. [Abstract] [PDF]

				L. Englberger, P. Markart, F.S. Eckstein, F.F. Immer, P.A. Berdat, and T.P. Carrel Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery Eur. J. Cardiothorac. Surg., October 1, 2002; 22(4): 545 - 551. [Abstract] [Full Text] [PDF]

				H. A. Hennein Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255. [Abstract] [PDF]

				J. M. Alvarez, L. R. Jackson, C. Chatwin, and J. J. Smolich Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: A prospective, randomized, double-blind, placebo-controlled trial J. Thorac. Cardiovasc. Surg., September 1, 2001; 122(3): 457 - 463. [Abstract] [Full Text] [PDF]

				M. Klein, P.R. Keith, H.-P. Dauben, H.D. Schulte, H. Beckmann, G. Mayer, O. Elert, and E. Gams Aprotinin counterbalances an increased risk of peri-operative haemorrhage in CABG patients pre-treated with Aspirin Eur. J. Cardiothorac. Surg., October 1, 1999; 14(4): 360 - 366. [Abstract] [Full Text] [PDF]

				S. C. Kettner, O. P. Panzer, S. A. Kozek, F. A. Seibt, B. Stoiser, J. Kofler, G. J. Locker, and M. Zimpfer Use of abciximab-Modified Thrombelastography in Patients Undergoing Cardiac Surgery Anesth. Analg., September 1, 1999; 89(3): 580 - 580. [Abstract] [Full Text] [PDF]

				J. J. Munoz, N. J. O. Birkmeyer, J. D. Birkmeyer, G. T. O'Connor, and L. J. Dacey Is {epsilon}-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? : A Meta-Analysis Circulation, January 12, 1999; 99(1): 81 - 89. [Abstract] [Full Text] [PDF]

				J. A. Hyde, J. A Chinn, and T. R Graham Platelets and cardiopulmonary bypass Perfusion, December 1, 1998; 13(6): 389 - 407. [PDF]

				O. Shigeta, H. Kojima, T. Jikuya, Y. Terada, N. Atsumi, Y. Sakakibara, T. Nagasawa, and T. Mitsui Aprotinin Inhibits Plasmin-Induced Platelet Activation During Cardiopulmonary Bypass Circulation, July 15, 1997; 96(2): 569 - 574. [Abstract] [Full Text]

				C. Baufreton, P. G. M. Jansen, P. Le Besnerais, H. Velthuis, C. M. Thijs, C. R. H. Wildevuur, and D. Y. Loisance Heparin Coating With Aprotinin Reduces Blood Activation During Coronary Artery Operations Ann. Thorac. Surg., January 1, 1997; 63(1): 50 - 56. [Abstract] [Full Text]

				R. G. H. Speekenbrink, A. B. A. Vonk, C. R. H. Wildevuur, and L. Eijsman Hemostatic Efficacy of Dipyridamole, Tranexamic Acid, and Aprotinin in Coronary Bypass Grafting Ann. Thorac. Surg., February 1, 1995; 59(2): 438 - 442. [Abstract] [Full Text]